Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't let the bashers/shorters fool you. Fear is your worst adviser. Buy hold and thank me later...
Totally agree. People are selling by fear at the moment...
It's no use to bash. Shorting is over. Isn't it Eddy?
Load your truck before you miss the boat
So do I. Buy, hold and thank me later. Up we go!
Dendreon is your pot of gold..
Good job!
Up to the top and high to the sky... Bam!
Nice post. Due to me I think it will hit the $5's.. Time is the primary asset. Buy, hold and thank me later...
Dendreon (OTCBB: DNDNQ) announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in the fourth quarter (adjusted for non-recurring items), starting 2015 on a strong footing. In addition, the first commercial European patient initiated treatment with PROVENGE (sipuleucel-T) in Germany – the first country outside of the U.S. to offer the novel immunotherapy for advanced prostate cancer since receiving marketing authorization in the European Union (EU) in 2013.
Dendreon finished 2014 strong with a net product revenue for the year ended December 31, 2014 of $303.8 million compared to $283.7 million for the year ended December 31, 2013. Net product revenue for the fourth quarter ended December 31, 2014 was $79.8 million compared to $74.8 million for the fourth quarter ended December 31, 2013. As of December 31, 2014, Dendreon had approximately $122 million in cash, cash equivalents, and short-term and long-term investments.
“Achieving these three major milestones – delivering four consecutive quarters of year over year growth, exceeding our target revenue and commercializing PROVENGE in Europe – starts 2015 on a positive note,” said W. Thomas Amick, president and chief executive officer of Dendreon. “Dendreon is moving in the right direction, and we are delivering on our commitment to expand access to PROVENGE for advanced prostate cancer patients worldwide.”
In early January, the first commercial patient in Germany began treatment with PROVENGE for advanced prostate cancer, demonstrating Dendreon’s continued commitment to bring the first personalized immunotherapy to patients in new markets. To help meet the need for innovative therapies for advanced prostate cancer in the EU, PROVENGE, which stimulates a patient’s own immune system to fight cancer, is being made available through a growing network of regional cancer treatment centers where select physicians are being trained in the treatment process. Initially, PROVENGE is available at four centers in Germany. Adding to the product’s broadening access, Dendreon has also registered PROVENGE in Puerto Rico, making it available for distribution.
“It is a privilege to be the first institution in the EU using a pioneering therapy like PROVENGE to treat advanced prostate cancer,” said Axel Heidenreich, MD, Uniklinik RWTH Aachen, Klinik for Urologie, Aachen, Germany. “The availability of PROVENGE in Europe gives physicians a brand-new way to fight this difficult-to-treat disease and may extend the lives of patients, who currently have limited effective therapies available.”
In 2012, approximately 417,000 men were diagnosed with prostate cancer in Europe, and more than 92,000 men died from the disease.1
PROVENGE is approved in the EU for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. Dendreon received marketing authorization for PROVENGE from the European Commission in September 2013, which provides approval for the commercialization of PROVENGE in all 28 countries of the EU as well as Norway, Iceland and Liechtenstein. The product is also approved by the Food and Drug Administration in the United States.
On November 10, 2014, Dendreon announced that it reached agreements on the terms of a financial restructuring with the Senior Noteholders of the Company's 2.875% Convertible Senior Notes due 2016, representing approximately 84% of the $620 million aggregate principal amount of the 2016 Notes. Under the terms of the agreements, the financial restructuring may take the form of a stand-alone recapitalization or a sale of the Company or its assets. To implement the financial restructuring contemplated under the agreements with the relevant Senior Noteholders, Dendreon and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The transactions under the agreements will enable continued delivery of PROVENGE without disruption or impact to access for providers and appropriate patients in need of this revolutionary personalized immunotherapy treatment.
$DNDN Strong results for Dendreon. Stock will fly today. Be smart and join the ride. Buy, hold & thank me later. Time is the primary asset
$DNDNQ Strong results for Dendreon. Stock will fly today. Be smart and join the ride. Buy, hold & thank me later. Time is the primary asset
Too funny shorts are bashing. Too bad it won't help. Dendreon recovers strong again. Back to a dollar. Get in and join the ride. Up!
It will. Get in and join the ride. Easy money. $$$$
Another green day for Dendreon. Almost 10% up at this moment. More to come. Get in and join the ride...
Dendreon starting to recover. Buy, hold and thank me later. Up we go!
Nice post! Totally agree. Time is the primary asset....
Good news..
The Debtors have determined not to select a stalking horse bid.
The Debtors have had active participation in the Competitive Process by a number of bidders and look forward to holding an Auction in connection with a Sale Transaction
On the move right now. Load your truck before you miss the boat...
Ready for a bump? Get in and join the ride. Buy, hold and thank me later. Time is the primary asset...
$DNDNQ Dendreon on the move right now. Get in and join the ride. Buy, hold and thank me later... ??
Best performing bio stock of today....
Dendreon testing it's high and lows today so you know what to do. Get in and join the ride. 5 % up right now. More to come.
Dendreon boiling right now. Any news will pop the stock. I'm ready. Who's with me? Get in and join the ride...
I guess it will pop right before close. Rumors about buyout after hours. When Warren Buffet is mentioned together with Dendreon you know what to do... I'm buying. As much as I can...
Totally agree. That's why I'm long and buying more. No matter what. Dare to think different. Risk versus reward is high...
And there's the news...
Dendreon Corporation (NASDAQ:DNDN) declared it reached agreements on the terms of a financial restructuring with certain holders...
Up we go!
Me like ??
Some nice buyings going on in the pre market.. Get in and join the ride..
Guess you didn't read it right... http://ih.advfn.com/p.php?pid=nmona&article=64381314&xref=newsalerttweet&adw=1126416
The bounce is now. Get in and join the ride..
So do I. Bought a truck load to see where she's going. Up from here. Up we go
Exactly. Get in and join the ride. $DNDN is preparing for a dead cat bounce.. Up she goes..
Downgraded to sell with a 22 dollar target... I'm out....
Remember. Never sell by fear. Tomorrow it will gain big time.. A drop of 30 percent is nothing after a delisting notice from te Nasdaq. Hold till tomorrow and you will be gratefull.
How' behind the 20,400 packages of 11 cents?
I'm in big time. Fasten your seatbelt and let the ride begin.
SCHS saved 30 mln dollar from the revised Bayside deal. Up we go...
I missed the letter D in the table... Just a Little detail..
10 cents seems to be the bottom. Up from here. Get in and join the ride